Background: Imbalanced cellular immunity is critical to the pathogenesis of systemic lupus erythematosus (SLE). Recently, autophagy has emerged as a key homeostatic mechanism in T lymphocytes. This study was conducted to explore the impact of autophagy on the Th17/ regulatory T (Treg) immune imbalance in SLE. Methods: Peripheral Th17 and Treg cells from newly diagnosed patients with SLE and healthy controls were detected by flow cytometry. Additionally, the effects of chloroquine (CQ) autophagic inhibition on the Th17/Treg immune response were investigated in vitro. In addition, hydroxychloroquine (HCQ) treatment of the Th17/Treg immune response and the disease progression of lupus MRL/lpr mice were studied in vivo. Results: Compared with healthy controls, both peripheral Th17 and Treg cells of patients with SLE exhibited activated autophagy, resulting in a heightened Th17 proinflammatory response and diminished Treg immunosuppression. Furthermore, in vitro experiments indicated that CQ autophagic inhibition effectively rebalanced the Th17/Treg immune responses in patients with SLE. In vivo studies of MRL/lpr mice similarly confirmed that HCQ treatment decisively inhibited the autophagy of Th17/Treg cellular subsets, restoring the immune balance, lowering the serum levels of inflammatory cytokines and autoantibodies, and improving renal histopathology. Conclusion: Activated autophagy contributed to the Th17/Treg immune imbalance in SLE, and chloroquine autophagic inhibition rebalanced Th17/ Treg-mediated immunity and ameliorated SLE.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease propagated by a host of inflammatory cytokines and autoantibodies, and it stems from imbalances in certain immune cell populations [1] [2] [3] . The impact of Th17/regulatory T (Treg) immune imbalances (i.e., elevated Th17 response, depressed Treg function) is critical to the pathogenesis of SLE [4] [5] [6] [7] , just like other autoimmune diseases [8] . Interleukin (IL)-17A, IL-17F, and IL-22 production by Th17 cells promotes the autoimmune response [9] . In conjunction with IL-21 and B-cell activating factor (BAFF), overproduction of IL-17 enhances germinal center formation, encouraging B cells to generate an abundance of pathogenic autoantibodies in SLE [10] . In contrast, Treg cells maintain immune homeostasis and suppress aberrant immune responses in a cytokine-dependent manner by releasing the immunosuppressive cytokines IL-10 and TGF-β. They also harbor a receptor protein, cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), latently expressing TGF-β on the membrane surface [11] . Although a large number of signaling pathways participate in the regulation of Treg cells [12] [13] [14] [15] , forkhead box protein 3 (Foxp3) as Treg specific transcription factor is the most important one. Diminished expression of Foxp3 in CD4 + CD25 + Treg cells created dysfunction of Treg cells in SLE [16] . Unfortunately, the mechanisms contributing to Th17/Treg immune imbalance in SLE remain unclear.
Recently, autophagy, an evolutionarily conserved cellular process that regulates the disassembly of unnecessary or dysfunctional cellular components in a lysosome-dependent manner [17] , has emerged as a key homeostatic mechanism in T lymphocytes, affecting T cell-mediated immunity and autoimmunity [18] [19] [20] . In particular, autophagic deregulation in T lymphocytes from humans and mice with SLE was implicated in abnormal T-cell responses [21] . Consequently, we tested the hypothesis that autophagy might be pivotal in the imbalance of Th17/Treg immunity responsible for the progression of SLE, with autophagic regulation helping to rebalance Th17/Treg cellular responses. Moreover, chloroquine (CQ) is known as an autophagy inhibitor that impairs autophagic flux by blocking autophagic degradation [22] , and hydroxychloroquine (HCQ), the hydroxylation of CQ, has been widely used as a basic drug for SLE treatment [23] .
This study aimed to investigate the role of CQ autophagic inhibition in the rebalance of Th17/Treg-mediated immunity in SLE based on studies of patients with SLE and spontaneous lupus-prone MRL-lpr/lpr mice.
Materials and Methods

Clinical materials
The study was conducted at the Affiliated Hospital of Guangdong Medical University (Zhanjiang, China), with approval from the Institutional Ethics Committee. All of the subjects, including newly diagnosed patients with SLE (n=12) and healthy volunteer controls (n=18), were recruited from the Department of Nephrology between December, 2014 and December, 2015, and all of them provided informed consent. The selected patients (male, 1; female, 11) were newly diagnosed with SLE, in accordance with modified SLE classification criteria formulated (1997) by the American College of Rheumatology (ACR). None had received glucocorticoids or other immunosuppressive agents, and they had no histories of hepatitis B, allergies, cancers, other severe systemic diseases, or other autoimmune disorders. Active disease was viewed as a SLE disease activity index (SLEDAI) score ≥10. Blood samples were collected from each healthy volunteer (male, 3; female, 15). The two population subsets did not differ significantly in terms of sex or age.
Animal models
Female MRL/MpJ-Faslpr/J mice (age, 12 weeks old; weight, 33±2 g) were supplied by the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Also known as MRL/lpr mutants, these mice develop a lupus-like systemic autoimmune disease, marked by proliferation of aberrant T cells and hyperfunctional autoreactive B cells. The animals were housed in a special pathogen-free environment (25°C, normal 12-h light/12-h dark cycle) in the Animal Center of Guangdong Medical University. The mice had unrestricted access to standard food and sterilized water supplied by the facility. A total of 20 female MRL/lpr mice were equally and randomly assigned to hydroxychloroquine (HCQ) treatment or control groups. Each HCQtreated mouse received daily oral gavage of HCQ (100 mg/kg; Sanofi, Paris, France) diluted in saline (500 μl), whereas the control mice were similarly administered equivalent volumes of saline only. All of the mice were euthanized after a 4-week treatment regimen, removing renal cortical tissue for histologic study. Blood samples were obtained by cardiac puncture of anaesthetized mice, separating the serum for enzymelinked immunosorbent assay (ELISA) and collecting peripheral blood mononuclear cells (PBMCs) for flow cytometry. All of the studies were approval by the Animal Experimentation Ethics Committee of Guangdong Medical University. Our experimental protocols conformed to approved guidelines.
Flow cytometric analysis (FCM)
Human and mouse blood samples were collected in anticoagulant-treated tubes. After centrifugation (to separate plasma), the supernatant was discarded, and the cell pellets were resuspended in red blood cell lysis buffer. PBMCs were isolated via Ficoll-Hypaque density-gradient centrifugation and were incubated (6 h) in complete RPMI 1640 medium with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) with or without chloroquine (CQ) (10 μmol/L; Sigma-Aldrich Corp, St. Louis, MO, USA).
For cytokine analysis, PBMCs were incubated (6 h) in Cell Stimulation Cocktail (plus protein transport inhibitors) (Thermo Fisher Scientific, Waltham, MA, USA) prior to fixation and permeabilization. LC3-II detection (as described previously) [24] entailed the washing of PBMCs (0.1% saponin in PBS) to extract the non-autophagosome-associated LC3-I before fixation.
After fixation and permeabilization, conjugated antibodies (direct or indirect) were applied to PBMCs for immunostaining, procuring the following antibodies and respective isotype controls (BioLegend, Inc., San Diego, CA, USA): anti-human CD4 (APC-eFlour780), anti-human IL-17A (PerCP-Cy 5.5), anti-human Foxp3 (eFlour660), anti-mouse CD4 (PE), anti-mouse/Rat IL-17A (PE-Cy7), and anti-mouse/Rat Foxp3 (APC). Rabbit anti-human LC3 (MBL International Corp, Woburn, MA, USA), rabbit anti-mouse LC3 (SigmaAldrich Corp), anti-human p62 (BD Biosciences, Franklin Lakes, NJ, USA) and respective isotype controls were obtained from other vendors. Fluorescein-labeled donkey anti-rabbit IgG (Alexa Fluor 488; Invitrogen) and the reagents for flow cytometry, including cell staining buffer, red blood cell lysis buffer (10×), fixation buffer, and permeabilization wash buffer (10×) (BioLegend, Inc.) were also purchased. All of the commercial reagents were stored and used according to manufacturers' recommendations.
ELISA ELISA kits were used to quantify levels of anti-nuclear antibody (ANA) and anti-dsDNA antibody (Alpha Diagnostic International, San Antonio, TX, USA) in mouse serum (1:100 dilution). Levels of IL-17, IFN-γ, and TGF-β in human and mouse serum were also quantified via ELISA (Life Technologies Corp, Grand Island, NY, USA). All of the analyses were performed as instructed by the manufacturer.
Western blotting
Protein was extracted from human PBMCs, and western blot analysis was performed as previously detailed [25, 26] . Primary antibodies to p62 protein and β-actin were purchased (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), as was anti-LC3B antibody (Sigma-Aldrich Corp). HRP-conjugated secondary antibodies were provided by the Beyotime Institute of Biotechnology (Nantong, Jiangsu, China).
Statistical analysis
All of the data are expressed as the mean±standard deviation (SD). To compare two groups, the independent sample t-test was applied. All of the computations relied on standard software (SPSS v16.0; SPSS Inc.
[IBM], Chicago, IL, USA), setting significance at p<0.05.
Results
Demographics and clinical characteristics of patients with SLE
Various parameters of the 12 patients with SLE, each newly diagnosed, are presented in Table 1 .
Patients with newly diagnosed SLE exhibit Th17/Treg imbalances, in conjunction with activated Th17/Treg autophagy
To first explore Th17/Treg immune responsiveness in SLE, we measured expression levels of IL-17 and Foxp3 in peripheral Th17 and Treg cells, respectively, using flow cytometry. As shown in Fig. 1A , patients with newly diagnosed SLE (vs. healthy controls) showed significantly greater IL-17 expression (in Th17 cells) but notably less Foxp3 expression (in Treg cells). We also measured IL-17, TGF-β, and IFN-γ levels in serum to further investigate the imbalances of Th17/Treg cells in SLE. Relative to healthy controls, proinflammatory IL-17 and IFN-γ levels were markedly upregulated in patients with newly diagnosed SLE (Fig.  1B and 1D ), whereas serum TGF-β levels were significantly reduced in comparison (Fig.  1C) . These data implicated Th17-cell overactivity and inhibition of Treg cells as immune derangements in patients with SLE.
To assess autophagic flux in immune cells from patients with SLE, we measured the expression of autophagic markers (LC3-II and p62) in peripheral PBMCs via western blotting, finding significantly greater LC3-II expression in cells from patients with newly diagnosed Finally, we analyzed autophagy in Th17 and Treg cells by flow cytometry. Compared with healthy controls, LC3-II was markedly elevated and p62 diminished in both Th17 and Treg cells, thus implying activation of Th17/Treg autophagy. These results suggested that imbalanced Th17/Treg immune responses in patients with SLE were accompanied by Th17/ Treg autophagic activation.
In vitro CQ autophagic inhibition restores balance between Th17 and Treg cells obtained from patients with SLE
We further investigated the effects of autophagic inhibition on the immune responses of Th17 and Treg cells, using CQ as autophagic inhibitor in an in vitro experiment. CQ acts to disrupt the fusion of autophagosomes with lysosomes and to suppress lysosomal degradation by increasing lysosomal pH [27] . Through western blot analysis, we first assessed autophagic flux in PBMCs from patients with SLE after in vitro CQ exposure. According to our data, CQ (vs. control) treatment produced significant upregulation of LC3-II and p62 expression levels in PBMCs (Fig. 3A) . Subsequently, these autophagic markers were analyzed in Th17 and Treg cells by flow cytometry. Again, levels of LC3-II and p62 were clearly elevated in both Th17 and Treg cells from patients with SLE after actual CQ exposure ( Fig. 3B and 3C ). As alluded to earlier, abundant p62, alongside LC3-II elevation, is a sign that autophagy in Th17 and Treg cells from patients with SLE patients was efficiently suppressed after CQ treatment. Interestingly, we also found that CQ (rather than control) treatment dramatically suppressed the expression of IL-17 in Th17 cells, with only a slight gain in Foxp3 expression by Treg cells from patients with SLE ( Fig. 3D and 3E ). This in vitro evidence suggested that autophagic inhibition by CQ could rebalance the immune responses of Th17 and Treg cells in patients with SLE.
In vivo HCQ autophagic inhibition rebalances immune responses of peripheral Th17 and Treg cells in MRL/lpr mice
To ascertain the role of autophagic inhibition in immune responses mediated by Th17 and Treg cells, we investigated the in vivo effects of HCQ (an autophagic inhibitory agent) 
HCQ autophagic inhibition suppresses autoimmune responses and alleviates pathologic changes in kidneys of MRL/lpr mice
Finally, we examined the effects of HCQ treatment on autoimmune responses in lupuslike mice, using ELISA to assess serum levels of IL-17 and IFN-γ as proinflammatory cytokines, anti-dsDNA IgG, and anti-nuclear IgG, as well as the immunosuppressive cytokine TGF-β. HCQ treatment of MRL/lpr mice resulted in significantly reduced serum concentrations of IL-17, IFN-γ, anti-dsDNA IgG, and anti-nuclear IgG (contrasting greatly with untreated controls), with a marginal increase in TGF-β (Fig. 5A and 5B). As shown in Fig. 5C , HCQ treatment also remarkably attenuated expected kidney changes, inhibiting mesangial cellular proliferation and suppressing renal tubular and interstitial infiltration by mononuclear/lymphocytic cells, in a clear departure from the controls. Thus, HCQ autophagic inhibition was capable of modulating aberrant immune responses and attenuating kidney injury in lupus-like mice.
Discussion
Herein, we substantiated the importance of autophagic activation as a critical accompaniment of the Th17/Treg imbalances that fuel the progression of SLE. Indeed, inhibition of autophagy by CQ or HCQ serves to dampen Th17 cellular responses and to promote the immunosuppressive effects of Treg cells, thus reducing proinflammatory cytokine levels and anti-dsDNA antibody production.
New information emerging about the balance between Th17 and Treg cells has offered a new paradigm for the immune underpinnings that control the onset and progression of SLE [4, 5] . In the present investigation, we determined that patients newly diagnosed with SLE patients (and therefore unexposed to immunosuppressive treatment) displayed increases in peripheral Th17 cells, with elevated levels of serum IL-17, IFN-γ and anti-dsDNA antibodies but diminished circulating Treg cells and serum levels of TGF-β, an immunosuppressive cytokine. Our findings indicated that Th17/Treg immune responses were indeed imbalanced in such patients, corresponding to data from human [6, 28] and experimental models [7] previously reported by other researchers. However, the driving force of Th17/Treg imbalance remains unclear [29] .
Recently, autophagy has been implicated in T-lymphocyte homeostasis and in T cellpredominant autoimmune diseases, including SLE [30] . Autophagy is a degradative process whereby cytoplasmic content is engulfed by lysosomes and destroyed [31] . It is well known that microtubule-associated protein 1 light chain 3 (LC3)-II and p62 are key markers used to monitor autophagic flux [26, 32] . An increase in LC3-II indicates a buildup of autophagic vacuoles, reflecting either increased formation or decreased clearance. In contrast, p62 is a ubiquitin-binding autophagic receptor and signaling protein, the accumulation of which denotes autophagy-lysosomal pathway disruption, culminating in aggregates of autophagic vacuoles [33] . Our data confirmed increased LC3 and diminished p62 expression levels in PBMCs from patients with SLE, indicating excessive autophagic activation, consistent with previous reports contending for a pivotal role of autophagy in the abnormal activation of T cells in SLE sufferers, all supported by genetic, cell-biology, and model-animal studies [21, 34, 35] . Hence, we presumed that autophagy might be critical in Th17/Treg immune imbalances due to progressive SLE.
To test this hypothesis, our first step was to assess autophagic activity in Th17 and Treg cells collected from patients with newly diagnosed SLE and healthy controls. We subsequently observed remarkable upregulation of LC3-II expression and diminished p62 expression in Th17 and Treg cells from these patients with SLE, based on flow cytometric analysis. One previous study postulated a constitutively higher level of autophagy in T-cell populations of patients with SLE [21] , but no other publications have addressed autophagy in T-cell subsets, not even Th17 and Treg cells. Nonetheless, our data confirmed autophagic activation in Th17 and Treg cells from patients with SLE, in conjunction with Th17/Treg immune imbalance. To then clarify the role of autophagic activation in Th17/Treg cells, we blocked the autophagic pathway, using CQ to inhibit autophagic-lysosomal degradation in vitro. As expected, CQ markedly enhanced LC3-II and p62 expression levels in both Th17 and Treg cells obtained from patients with SLE. At the same time, IL-17 expression in Th17 cells was significantly suppressed, with a slight upturn in Foxp3 expression by Treg cells. These outcomes were further affirmed in HCQ-treated MRL/lpr lupus-like mice, in which decisive upregulation of LC3-II and p62 expression in peripheral Th17 and Treg cells, a significant decrease in IL-17 expression by Th17 cells, and upregulation of Foxp3 expression in Treg cells were all evident. Additionally, HCQ treatment substantially reduced serum levels of IL-17 and IFN-γ, suppressing autoantibody production and alleviating kidney damage in these animals. Thus, the use of autophagic-lysosomal inhibitors to downregulate excessive autophagic activation could potentially correct the perceived imbalances of Th17/Treg cells in SLE and attenuate immune manifestations.
Notably, we found that downregulation of autophagy in both Th17 and Treg cells of patients with SLE dampened Th17 immune responses while also promoting Treg immunosuppressive effects. Therefore, it seems that the effects of autophagy on diverse T-cell subsets might actually differ. Similarly, inhibition of autophagy reduces IL-17 secretion by reversing the overactivity of Th17 cells observed in SLE, whereas Foxp3 in Treg cells increases during the course of autophagic inhibition (Fig. 6) . A potential explanation is that autophagic-lysosomal inhibitors could block lysosome-dependent degradation of Foxp3, which is crucial for Treg cellular differentiation or function. Clearly, CQ does prevent lysosomedependent degradation of Foxp3, preserving Treg-cell functionality [36] . This phenomenon was similarly described in an earlier report of reduced severity of experimental autoimmune encephalomyelitis, achieved through CQ-induced enhancement of Treg functionality [37] . However, the means by which such differential autophagic regulation occurs will require further research. It might depend upon metabolic factors, with degradation of specific proteins mediated by the autophagic process.
In this study, CQ (HCQ) was employed as an autophagic inhibitor to downregulate autophagy but not by RNA interference due to safety concerns of RNAi delivery with viral vectors or with nonviral delivery methods with the potential to activate Th17/Treg cells from SLE patients. In another aspect, autophagy-knockout lupus mice were still not obtained.
In conclusion, activated autophagy contributed to Th17/Treg immune imbalance in SLE, and CQ (HCQ) autophagic inhibition rebalanced Th17/Treg-mediated immunity and ameliorated SLE.
